Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed for a remedy for liver fibrosis and cirrhosis, was evaluated to evaluate the effect of hepatic impairment on its pharmacokinetics and security to deal with regulatory specifications. Desk four Statistical assessment of dose proportionality with the pharmacokinetic parameters of GB1211 https://joanb333qcn6.empirewiki.com/user